GABA-A, nicotinic, muscarinic, and monoaminergic receptors

GABA-A, nicotinic, muscarinic, and monoaminergic receptors refers to a broad collection of distinct neurotransmitter receptor families rather than a single molecular entity. GABA-A receptors are ligand-gated chloride channels that mediate fast inhibitory neurotransmission in the central nervous system (Sigel & Steinmann, 2012, Journal of Biological Chemistry). Nicotinic acetylcholine receptors (nAChRs) are pentameric ligand-gated ion channels that facilitate excitatory signaling at the neuromuscular junction and within the brain (Albuquerque et al., 2009, Physiological Reviews). Muscarinic acetylcholine receptors (mAChRs) are G protein-coupled receptors (GPCRs) that modulate various physiological functions, including heart rate and smooth muscle contraction (Kruse et al., 2014, Nature Reviews Drug Discovery). Monoaminergic receptors comprise a large group of GPCRs that respond to monoamine neurotransmitters such as dopamine, serotonin, and norepinephrine, playing vital roles in mood, reward, and autonomic function (Gainetdinov et al., 2018, Pharmacological Reviews). Due to their diverse structures and signaling pathways, these receptors are involved in a wide array of pathologies, including epilepsy, Alzheimer's disease, schizophrenia, and depression (Millan et al., 2015, Nature Reviews Drug Discovery). While many pharmacological agents, such as atypical antipsychotics, target multiple receptors within these groups to achieve therapeutic effects, the grouping itself is too broad to be classified as a single therapeutic target (IUPHAR/BPS Guide to PHARMACOLOGY).

Other names

GABA-A receptorNicotinic acetylcholine receptorMuscarinic acetylcholine receptorMonoaminergic receptorNeurotransmitter receptors

Drugs targeting these receptors act through diverse mechanisms: GABA-A modulators enhance inhibitory chloride conductance; nicotinic and muscarinic agents act as agonists or antagonists to modulate cholinergic tone; and monoaminergic drugs modulate signaling across dopamine, serotonin, and adrenergic pathways (IUPHAR/BPS Guide to PHARMACOLOGY).